共 65 条
[1]
Siegel RL(2017)Cancer statistics, 2017 CA Cancer J Clin 67 7-30
[2]
Miller KD(2014)Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors SpringerPlus 3 535-219
[3]
Jemal A(2017)The Growing role of CDK4/6 inhibitors in treating hormone receptor-positive advanced breast cancer Curr Treat Options Oncol 18 6-35
[4]
Weide R(2015)Palbociclib in hormone-receptor-positive advanced breast cancer N Engl J Med 373 209-439
[5]
Feiten S(2015)The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study Lancet Oncol. 16 25-1936
[6]
Friesenhahn V(2016)Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Lancet Oncol. 17 425-3646
[7]
Heymanns J(2016)Palbociclib and letrozole in advanced breast cancer N Engl J Med 375 1925-1748
[8]
Kleboth K(2017)MONARCH 3: abemaciclib as initial therapy for advanced breast cancer J Clin Oncol 35 3638-1423
[9]
Thomalla J(2016)Ribociclib as first-line therapy for hr-positive, advanced breast cancer N Engl J Med 375 1738-1545
[10]
Shah AN(2016)Clinical and economic outcomes by first-line treatment among women with HR+/HER2− metastatic breast cancer in a large US health plan database Curr Med Res Opin 32 1417-1016